PATENT CLAIM ANALYSIS

Application Number: 15755262
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "054000"]

Abstract:
A pharmaceutical composition including N,N,N′,N′-tetrakis-(2-pyridylmethyl)-ethylenediamine (TPEN) or a pharmaceutically acceptable salt thereof, an alginate compound, and a pharmaceutically acceptable carrier. The pharmaceutical composition is useful for the treatment of hypoxia-related diseases.

Claim (Index 15):
The method of  claim 14 , wherein said hypoxia-related disease is selected from a group consisting of ischemic-reperfusion injury (IRI), cardiovascular disease, ischemic heart disease, ischemic brain condition, macular degeneration, ocular ischemic syndrome, ischemic optic neuropathy (ION), diabetic retinopathy, arthritis, inflammation, sepsis, sepsis-induced shock, renal disease, tissue fibrosis, gastrointestinal disease, neurodegenerative disease, respiratory distress syndrome, bronchopulmonary displasia, pulmonary hypertension, hypoxic pulmonary hypertension, severe pulmonary hypertension, COPD, diabetic retinopathy, diabetes, corneal neovascularization, pathogenic blood vessel growth and musculoskeletal disorder.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 88.0
- Lexical Diversity: 1.38235
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14255643', '14415163', '12594812', '15345842', '13809154']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7810758667087142
- 35 USC 102 Novelty (BERT): 0.4947703217207343
- Combined Prediction Score: 0.7524453122099163
- Mean Citation Score: 175.33369
- Max Citation Score: 187.93503
- Similarity Product: 120.23627533731936

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test